Lotense 5 mg Capsule Actions

• Actions of Lotense 5 mg Capsule in details
• Lotense 5 mg Capsule administration
• Lotense 5 mg Capsule pharmacology
• Lotense 5 mg Capsule reviews

Actions of Lotense 5 mg Capsule in details

Lotense 5 mg Capsule is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that Lotense 5 mg Capsule binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Lotense 5 mg Capsule inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by Lotense 5 mg Capsule. Within the physiologic pH range, Lotense 5 mg Capsule is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect.

Lotense 5 mg Capsule is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.

The precise mechanisms by which Lotense 5 mg Capsule relieves angina have not been fully delineated, but are thought to include the following:

Exertional Angina

In patients with exertional angina, Lotense 5 mg Capsule reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.

Vasospastic Angina

Lotense 5 mg Capsule has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro. This inhibition of coronary spasm is responsible for the effectiveness of Lotense 5 mg Capsule in vasospastic (Prinzmetal’s or variant) angina.

How should I take Lotense 5 mg Capsule?

Take Lotense 5 mg Capsule exactly as prescribed by your doctor. Follow all directions on your prescription label. Your doctor may occasionally change your dose to make sure you get the best results. Do not use this medicine in larger or smaller amounts or for longer than recommended.

You may take Lotense 5 mg Capsule with or without food. Take the medicine at the same time each day.

Your blood pressure will need to be checked often.

Your chest pain may become worse when you first start taking Lotense 5 mg Capsule or when your dose is increased. Call your doctor if your chest pain is severe or ongoing.

If you are being treated for high blood pressure, keep using Lotense 5 mg Capsule even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medicine for the rest of your life.

Your hypertension or heart condition may be treated with a combination of drugs. Use all medications as directed by your doctor. Read the medication guide or patient instructions provided with each medication. Do not change your doses or stop taking any of your medications without your doctor's advice. This is especially important if you also take nitroglycerin.

Lotense 5 mg Capsule is only part of a complete program of treatment that may also include diet, exercise, weight control, and other medications. Follow your diet, medication, and exercise routines very closely.

Store at room temperature away from moisture, heat, and light.

Lotense 5 mg Capsule administration

Oral: Administer without regard to meals.

Lotense 5 mg Capsule pharmacology

Mechanism of Action

Lotense 5 mg Capsule is a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that Lotense 5 mg Capsule binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. Lotense 5 mg Capsule inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by Lotense 5 mg Capsule. Within the physiologic pH range, Lotense 5 mg Capsule is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect.

Lotense 5 mg Capsule is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.

The precise mechanisms by which Lotense 5 mg Capsule relieves angina have not been fully delineated, but are thought to include the following:

Exertional Angina

In patients with exertional angina, Lotense 5 mg Capsule reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.

Vasospastic Angina

Lotense 5 mg Capsule has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro. This inhibition of coronary spasm is responsible for the effectiveness of Lotense 5 mg Capsule in vasospastic (Prinzmetal’s or variant) angina.

Pharmacodynamics

Hemodynamics

Following administration of therapeutic doses to patients with hypertension, Lotense 5 mg Capsule produces vasodilation resulting in a reduction of supine and standing blood pressures. These decreases in blood pressure are not accompanied by a significant change in heart rate or plasma catecholamine levels with chronic dosing. Although the acute intravenous administration of Lotense 5 mg Capsule decreases arterial blood pressure and increases heart rate in hemodynamic studies of patients with chronic stable angina, chronic oral administration of Lotense 5 mg Capsule in clinical trials did not lead to clinically significant changes in heart rate or blood pressures in normotensive patients with angina.

With chronic once daily oral administration, antihypertensive effectiveness is maintained for at least 24 hours. Plasma concentrations correlate with effect in both young and elderly patients. The magnitude of reduction in blood pressure with Lotense 5 mg Capsule is also correlated with the height of pretreatment elevation; thus, individuals with moderate hypertension (diastolic pressure 105 to 114 mmHg) had about a 50% greater response than patients with mild hypertension (diastolic pressure 90 to 104 mmHg). Normotensive subjects experienced no clinically significant change in blood pressures (+1/–2 mmHg).

In hypertensive patients with normal renal function, therapeutic doses of Lotense 5 mg Capsule resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or proteinuria.

As with other calcium channel blockers, hemodynamic measurements of cardiac function at rest and during exercise (or pacing) in patients with normal ventricular function treated with Lotense 5 mg Capsule have generally demonstrated a small increase in cardiac index without significant influence on dP/dt or on left ventricular end diastolic pressure or volume. In hemodynamic studies, Lotense 5 mg Capsule has not been associated with a negative inotropic effect when administered in the therapeutic dose range to intact animals and man, even when coadministered with beta-blockers to man. Similar findings, however, have been observed in normal or well-compensated patients with heart failure with agents possessing significant negative inotropic effects.

Electrophysiologic Effects

Lotense 5 mg Capsule does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man. In patients with chronic stable angina, intravenous administration of 10 mg did not significantly alter A-H and H-V conduction and sinus node recovery time after pacing. Similar results were obtained in patients receiving Lotense 5 mg Capsule and concomitant beta-blockers. In clinical studies in which Lotense 5 mg Capsule was administered in combination with beta-blockers to patients with either hypertension or angina, no adverse effects on electrocardiographic parameters were observed. In clinical trials with angina patients alone, Lotense 5 mg Capsule therapy did not alter electrocardiographic intervals or produce higher degrees of AV blocks.

Drug interactions

Sildenafil: When Lotense 5 mg Capsule and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.

Pharmacokinetics

After oral administration of therapeutic doses of Lotense 5 mg Capsule, absorption produces peak plasma concentrations between 6 and 12 hours. Absolute bioavailability has been estimated to be between 64 and 90%. The bioavailability of Lotense 5 mg Capsule is not altered by the presence of food.

Lotense 5 mg Capsule is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. Ex vivo studies have shown that approximately 93% of the circulating drug is bound to plasma proteins in hypertensive patients. Elimination from the plasma is biphasic with a terminal elimination half-life of about 30 to 50 hours. Steady-state plasma levels of Lotense 5 mg Capsule are reached after 7 to 8 days of consecutive daily dosing.

The pharmacokinetics of Lotense 5 mg Capsule are not significantly influenced by renal impairment. Patients with renal failure may therefore receive the usual initial dose.

Elderly patients and patients with hepatic insufficiency have decreased clearance of Lotense 5 mg Capsule with a resulting increase in AUC of approximately 40 to 60%, and a lower initial dose may be required. A similar increase in AUC was observed in patients with moderate to severe heart failure.

Drug interactions

In vitro data indicate that Lotense 5 mg Capsule has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin.

Impact of other drugs on Lotense 5 mg Capsule

Co-administered cimetidine, magnesium-and aluminum hydroxide antacids, sildenafil, and grapefruit juice have no impact on the exposure to Lotense 5 mg Capsule.

CYP3A inhibitors

Co-administration of a 180 mg daily dose of diltiazem with 5 mg Lotense 5 mg Capsule in elderly hypertensive patients resulted in a 60% increase in Lotense 5 mg Capsule systemic exposure. Erythromycin co-administration in healthy volunteers did not significantly change Lotense 5 mg Capsule systemic exposure. However, strong inhibitors of CYP3A (e.g., itraconazole, clarithromycin) may increase the plasma concentrations of Lotense 5 mg Capsule to a greater extent.

Impact of Lotense 5 mg Capsule on other drugs

Co-administered Lotense 5 mg Capsule does not affect the exposure to atorvastatin, digoxin, ethanol and the warfarin prothrombin response time.

Simvastatin

Co-administration of multiple doses of 10 mg of Lotense 5 mg Capsule with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone.

Cyclosporine

A prospective study in renal transplant patients (N=11) showed on an average of 40% increase in trough cyclosporine levels when concomitantly treated with Lotense 5 mg Capsule.

Tacrolimus

A prospective study in healthy Chinese volunteers (N=9) with CYP3A5 expressers showed a 2.5-to 4-fold increase in tacrolimus exposure when concomitantly administered with Lotense 5 mg Capsule compared to tacrolimus alone. This finding was not observed in CYP3A5 non-expressers (N= 6). However, a 3-fold increase in plasma exposure to tacrolimus in a renal transplant patient (CYP3A5 non-expresser) upon initiation of Lotense 5 mg Capsule for the treatment of post-transplant hypertension resulting in reduction of tacrolimus dose has been reported. Irrespective of the CYP3A5 genotype status, the possibility of an interaction cannot be excluded with these drugs.

Pediatric Patients

Sixty-two hypertensive patients aged 6 to 17 years received doses of Lotense 5 mg Capsule between 1.25 mg and 20 mg. Weight-adjusted clearance and volume of distribution were similar to values in adults.

References

1. NCIt. "Amlodipine: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser... (accessed September 17, 2018).
2. EPA DSStox. "Amlodipine: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/ds... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Lotense 5 mg Capsule are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lotense 5 mg Capsule. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 14 here

Information checked by Dr. Sachin Kumar, MD Pharmacology